Next Article in Journal
Strategies and Mechanism in Reversing Intestinal Drug Efflux in Oral Drug Delivery
Previous Article in Journal
Antipsoriatic Potential of Quebecol and Its Derivatives
Previous Article in Special Issue
Rational Development of a Carrier-Free Dry Powder Inhalation Formulation for Respiratory Viral Infections via Quality by Design: A Drug-Drug Cocrystal of Favipiravir and Theophylline
 
 
Article

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations

Small Molecules R&D, Lonza Group AG, Bend, OR 97703, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Khaled Assi
Pharmaceutics 2022, 14(6), 1130; https://doi.org/10.3390/pharmaceutics14061130
Received: 28 April 2022 / Revised: 21 May 2022 / Accepted: 24 May 2022 / Published: 26 May 2022
Spray drying is a particle engineering technique used to manufacture respirable pharmaceutical powders that are suitable for delivery to the deep lung. It is amenable to processing both small molecules and biologic actives, including proteins. In this work, a simultaneous spray-drying process, termed simul-spray, is described; the process involves two different active pharmaceutical ingredient (API) solutions that are simultaneously atomized through separate nozzles into a single-spray dryer. Collected by a single cyclone, simul-spray produces a uniform mixture of two different active particles in a single-unit operation. While combination therapies for dry powder inhalers containing milled small molecule API are commercially approved, limited options exist for preparing combination treatments that contain both small molecule APIs and biotherapeutic molecules. Simul-spray drying is also ideal for actives which cannot withstand a milling-based particle engineering process, or which require a high dose that is incompatible with a carrier-based formulation. Three combination case studies are demonstrated here, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation. These model systems were chosen for their potential relevance to the local treatment of lung cancer. The resulting formulations preserved the biologic activity of the antibody, achieved target drug concentration, and had aerosol properties suitable for pulmonary delivery. View Full-Text
Keywords: spray drying; dry powder inhaler; pulmonary delivery; combination therapy; lung cancer; particle engineering spray drying; dry powder inhaler; pulmonary delivery; combination therapy; lung cancer; particle engineering
Show Figures

Figure 1

MDPI and ACS Style

Shepard, K.B.; Pluntze, A.M.; Vodak, D.T. Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations. Pharmaceutics 2022, 14, 1130. https://doi.org/10.3390/pharmaceutics14061130

AMA Style

Shepard KB, Pluntze AM, Vodak DT. Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations. Pharmaceutics. 2022; 14(6):1130. https://doi.org/10.3390/pharmaceutics14061130

Chicago/Turabian Style

Shepard, Kimberly B., Amanda M. Pluntze, and David T. Vodak. 2022. "Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations" Pharmaceutics 14, no. 6: 1130. https://doi.org/10.3390/pharmaceutics14061130

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop